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ABSTRACT 
Drug utilization (DU) is systematic regulatory approach designed to identify diversity of drugs use and to evaluate the ratio nal use of medicines 
in population. Anticoagulants are drugs used to avoid thrombus extension and embolic consequences with associated risks related to their 
administration. Objectives: The objectives of the present study were to evaluate the drug prescription pattern of anticoagulants, observe and 
report drug interactions and adverse drug reactions among patients using anticoagulants. Method: Utilization of anticoagulant drugs was 
evaluated in 50 patients from 4 wards (dialysis, medicine, orthopedic and intensive-care unit) of a tertiary care teaching hospital in a cross-
sectional, prospective study conducted for 4 months i.e. from 1st January 2018 to 30th April 2018. Results: LMWH (enoxaparin) was the 
maximum preferred parenteral anticoagulant prescribed to 31 % of patients as prophylaxis for deep vein thrombosis followed by heparin. 
14(28%) of total population were administered combination therapy and 36 (72%) patients received only one anticoagulant drug during 
hospitalization. The most prescribed drug combination was enoxaparin+warfarin followed by enoxaparin+acenocoumarol. For discharge 
medicines, 14 patients were prescribed oral anticoagulants; 9 (64.3%) patients were prescribed with warfarin and the remaining 5 (35.7%) 
patients were given acenocoumarol. 28(56%) patient’s laboratory tests were evaluated for parameters like prothrombine time (P T) and 
international normalized ratio (INR). In the remaining 22(44%) patients, the above tests were not performed. Sixteen drug interactions were 
identified, ten were pharmacodynamics and the rest six were pharmacokinetic interactions. Three adverse drug reactions were reported during 
the study. The need for dosage adjustment in different diagnostic situations or specific populations is very crucial. Conclusion: The therapy 
with these drugs needs to be cost effective and reduce the complications associated with their use. 
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Drug utilization study is essential to evaluate prescription 
patterns, rational use of drugs and to develop interventions 
for improvement quality of life that will enhance proper and 
safe administration of medicines. Absence of essential drug 
prescription policy, irrational drug utilization and the 
prevalence of self-medication, all these factors lead poor 
access to healthcare1. Inadequate knowledge of suitable 
prescription and utilization leads to increase drawbacks in 
evaluating the therapeutic value, cost effectiveness and 
adverse effects. 
A venous thrombosis (VT) refers to a blood clot that starts in 
a vein. Deep vein thrombosis (blood thrombus in the deep 
veins) is associated with pain and swelling, usually in the 
thigh, pelvis and axillary vein and often takes place without 
symptoms. Thrombus formed in large veins prone to break 
off and trapped in pulmonary artery and ultimately impedes 
blood supply causing a pulmonary embolism (PE). Each year, 
approximately 1,000,000 Americans acquire VTE, and 
100,000 deaths occur as a result. VTE is therefore estimated 
to produce 5–10% of all deaths among hospitalized patients 
and therefore, it has become an economic burden for health 
care. A retrospective study was conducted in India aimed to 
Alzubaidi et al                                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):181-185 
ISSN: 2250-1177                                                                                  [182]                                                                                 CODEN (USA): JDDTAO 
study prevalence of VTE in high risk hospitalized patients, 
the incidence of VTE was 17.46 per 10 000 admissions 2.  
A homeostatic mechanism between coagulation cascade and 
fibrinolytic system in human body is maintained by 
coagulation factors. Anticoagulants reduce blood tendency 
for coagulation, either by direct inhibition of coagulation 
factors or by interfering with their synthesis. Anticoagulants 
do not lyse a formed clot, but they used as prophylactic and 
prevent recurrences. According to the National Health 
Service (NHS) England (2013) National VTE Prevention 
programme, evaluation of hospitalized patients who are at 
risk to develop VT should be considered. Anticoagulants are 
effective for venous fibrin clot and have questionable value 
in arterial thrombi (platelet clot). They are indicated for 
prevention and treatment of different kinds of 
cardiovascular diseases like DVT, PE, myocardial infarction 
(MI), unstable angina, prosthetic heart valve, major vascular 
operations 3. Heparin is used in vitro during a blood 
transfusion and laboratory investigations. Anticoagulants 
treatment monitoring is essential to avoid adverse events 
like bleeding by over coagulation, and thrombosis due to 
under coagulation. Because anticoagulants act by different 
modes of action and have a narrow window for therapeutic 
dosing, their administration requires special attention. To 
improve quality of the treatment and to adjust medicine 
intake, predictive models were introduced. 
When rapid and consistent anticoagulation is required, 
heparin is first indicated as initial therapy, followed by oral 
anticoagulants as maintenance dose. Multiple drug-drug and 
drug-food interactions in addition to drug response 
variations between patients increase the difficulties for 
optimal treatment with vitamin K antagonists (VKA). Direct 
oral anticoagulants (DOACs) like apixaban, rivaroxaban, 
edoxaban and dabigatran are a novel class of agents that 
were introduced for acute and long-term treatment of VTE 4. 
Achieving the goal of proper usage requires special control 
and strict clinical and laboratory follow up. It is very 
important to identify and develop new standards not only to 
improve efficacy and safety of anticoagulants utilization, but 
also to minimize the complications and the cost of 
administration. 
2. METHODS 
2.1 Study Design  
The study was prospective, cross-sectional and non-
interventional to evaluate the prescription pattern of 
anticoagulants on the basis of physicians prescribing 
records, patient’s pro-forma and questionnaire data. Study 
was carried out in the HAH Centenary Hospital, Jamia 
Hamdard, New Delhi. Patients hospitalized in HAH Centenary 
Hospital using anticoagulants were counseled and their 
spontaneous ADRs were reported and analyzed using ADR 
reporting form and WHO-UMC scale. Patient’s eligibility 
inclusion criteria were: Patients of both sexes having more 
than 18 years of age who utilized anticoagulant drugs during 
hospitalization. The study included a total of 50 patients, 
utilized anticoagulant drugs either for treatment or 
prophylaxis along the study period of 4 months.  
2.2 Data Collection 
Collected demographic data of patients include age, race, sex, 
height, weight, medical history, underlying disease and 
indication(s) for anticoagulant therapy. Another data 
obtained from patient’s medical record like kidney and liver 
function markers, concomitant medications, duration of 
anticoagulant therapy, drug-drug/food interactions. Various 
laboratory investigations related to diagnosis and 
monitoring of anticoagulant therapy were assessed like PT, 
INR and aPTT. Data for the study were assessed by referring 
patient’s medication profile, case records, laboratory reports 
and study pro-forma. Patient’s adherence to the therapy on 
the basis of data obtained during admission using medication 
compliance questionnaire and spontaneous ADRs were 
reported and analyzed using ADR reporting form and WHO-
UMC scale  
2.3 Statistical Analysis 
By using Microsoft excel, data were analyzed by using 
descriptive statistical parameters namely, mean, standard 
deviation and percentage. Stockley’s drug interaction, 8th 
Edition used as resource to measure the severity level of 
drug-drug interactions. WHO-UMC causality assessment 
scale was used to observe ADRs. 
3. OBSERVATION AND RESULTS 
Fifty patients included in the study who received 
anticoagulants with different disease conditions. Out of 50 
patients, 21(42%) were male patients with mean age of 
59.19 years, and 29(58%) were female patients with mean 
age of 54 years. The study subjects were classified into 
four age groups;  18(36%)  belonged to age group of 56 to 70 
years covered majority of patients in the study, followed by 
14(28%) patients in age group of 41 to 55 years. Patients in 
age group of 25 to 40 and 71 to 86 years were found to be 
same in distribution which was nine (18%) Fig. 1. 
 
 
Figure 1: Prevalence of Patients Administered Anticoagulant among Different Age Groups 
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Total number of patients on single drug therapy was 36 
(72%), out of which 20 (55%) patients were on Enoxaparin, 
followed by heparin which was prescribed to 13 (36%) 
patients. Two patients were prescribed with VKAs (warfarin 
and acenocoumarol). Only one patient was prescribed with 
fondaparinux. Among total patients received anticoagulant 
drugs, 14 (28%) were on drug combination therapy. This 
combination therapy included parenteral and oral drugs. 
The most utilized combination therapy was 
enoxaparin+warfarin which were prescribed to seven (50%) 
patients, followed by enoxaparin+acenocoumarol prescribed 
to 3 (21%) female patients. The least utilized combination 
was heparin+acenocoumarol which prescribed only to one 
patient Fig. 2. For discharge medicine, 14 (28%) patients 
were prescribed oral anticoagulants, 9 (64.3%) patients 
were administered warfarin and the remaining 5 (35.7%) 
patients were given acenocoumarol. Concurrent use of 
antiplatelet drugs (asprin, clopidogrel) was also observed 
during the study. 
 
 
Figure 2: Combination Anticoagulant Drugs Utilization 
 
Patient’s laboratory test parameters like PT and INR were 
evaluated only for 28 (56%) of patients. These tests were 
repeated in 8 (28.5%) patients to monitor the efficacy and 
predict over coagulation effect of anticoagulant therapy. 
Most anticoagulants were prescribed in ICU Fig. 3. 
 
   
Figure 3: Anticoagulant Drugs Utilized In Different Hospital Wards 
 
Total of three adverse drug reactions were reported 
spontaneously. One was with heparin; one was with 
enoxaparin and one ADR was with warfarin TABLE 1. WHO-
UMC causality assessment scale was used to assess the 
causality and the result was probable ADR with heparin and 
enoxaparin, and possible ADR with warfarin. Few ADRs 
were observed, mild thrombocytopenia by heparin, 
hematoma by enoxaparin and nausea and abdominal pain by 
warfarin.
 
Table 1: Spontaneous Adverse Drug Reaction Reporting 
S. No. Drug class Adverse drug reaction No. of patients Causality Assessment 
1 Heparin Thrombocytopenia 
(Platelets =87000 /ul) 
1 Probable/Certain 
2 Enoxaparin Heamatoma 1 Probable 
3 Warfarin Nausea, abdominal pain 1 Possible 
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The patient’s medication chart was evaluated for drug 
interactions involving anticoagulants. A total sixteen drug 
interactions were identified. In eight of interaction, warfarin 
was involved in interaction with other drugs like isoniazid, 
clindamycin, phenytoin, diltiazem, asprin and NSAIDs. Four 
interactions were observed involving heparin with drugs like 
aspirin, clopidogrel, piperacillin and NSAIDs. Enoxoparin 
with pentoxyfylline and acenocoumarol with amiodaron, 
sulfamethoxazol, oral contraceptive (levonorgestrel) and 
diltiazem were the other interactions identified. Out of 
sixteen interactions, ten were pharmacodynamics and the 
rest six were pharmacokinetic interactions. The 
pharmacokinetic drug interaction between acenocoumarol 
and amiodarone is due to the mechanism that 
acenocoumarol acts by inhibition of vitamin K synthesis, and 
amiodarone acts by inhibiting the action of cytochrome P450 
isozyme, this interaction results in increased anticoagulant 
activity. Interaction between heparin and piperacillin, results 
in increased anticoagulant activity with the mechanism 
involved being inhibition of platelet aggregation by 
piperacillin. One more interaction was observed in 
combination of warfarin with phenytoin, this combination 
increased prothrombin time. The mechanism of 
pharmacodynamic interaction was found to be a synergistic 
action involving drugs like acenocoumarol with 
clarithromycin and enoxaparin. Anticoagulant drugs were 
prescribed for patients having different disease conditions as 
shown below in TABLE 2. 
 
Table 2: Reasons for Anticoagulant Drugs Administration 
Cardiovascular conditions No. of cases Non cardiovascular conditions No. of cases 




Metric valve stenosis 
Cardiopulmonary arrest 












 Bone fracture  









Note:  Inferior vena cava (IVC), Chronic kidney disease (CKD), Acute kidney injury (AKI). 
 
4. DISCUSSION 
The study was conducted to evaluate the prescription 
pattern of anticoagulant drugs among patients admitted in 
different wards at HAH centenary hospital, a tertiary care 
teaching hospital of Jamia Hamdard, associated HIMSR, New 
Delhi. 
The present study showed that the anticoagulants 
prescription based on international guidelines with a little 
deviation. The pattern of use did not always correspond with 
American College of Chest Physicians (ACCP) guidelines and 
in some cases the prescription based on patient’s 
requirements. Over four months of study on patients age 
ranged from 25 to 86 years, it was observed that there were 
three (6%) of wrong prescription of anticoagulants where 
patients were prescribed anticoagulant therapy without any 
indication. Research on drug utilization and safety of 
LMWHs conducted by Philippe et al. (2007) showed that 
there was number of cases (11 patients) out of 400 patients 
were administered anticoagulants despite, there was not any 
indications for anticoagulants to be used 5. Our study 
showed LMWH (enoxaparin) was the maximum preferred 
parenteral anticoagulant which prescribed to 31 % of 
patients followed by heparin. In India, cross sectional study 
conducted by Vijay et al. [2015] in 84 patients to evaluate 
utilization of anticoagulants had reported that 
acenocoumarol was the most anticoagulant prescribed for 
38% of patients followed by enoxaparin administered for 
31% of the total patients 6. During prescribing LMWH, dose 
adjustment has to be done in patients having renal 
impairment which was not seen in three of cases of total 
enoxaparin indicated cases. ACCP guidelines point out that 
patients who have creatinine clearance ClCr <30 ml/min 
should receive LMWH after dosage adjustment (30 mg s.c 
qday), dose commonly administered was found to be 40 
mg/day. Some studies suggested increase in potassium level 
when treated with LMWH which was not seen in this study 7. 
In our study, UFH was the second most used parenteral 
anticoagulant where the initial dose was 5000 IU. In the 
present study we found that UFH was preferred in 17 cases 
used in conditions like coronary heart disease, ischemic 
stroke and in haemodialysis unit, and in many cases aPTT 
was not performed as per the laid down guidelines,  this can 
result in administering an in appropriate dosage to the 
patient resulting in bleeding and thrombosis. 
The analysis of patients utilized anticoagulant therapy 
showed that 14 (28%) of patients were administered 
combination therapy. Mostly prescribed drug combination 
was enoxaparin+warfarin followed by enoxaparin+ 
acenocoumarol. 
From observation of our study, most of the anticoagulant 
drugs (36%) were administered in the intensive care unit 
Fig. 10. Warfarin was prescribed more than acenocoumarol 
at the time of discharge at a dose of 5mg for patients with 
coronary artery disease, dilated cardiomyopathy, metric 
valve stenosis and CKD. Acenocoumarol was used in patients 
with rheumatic heart disease, atrial fibrillation and vascular 
lesions. Heparin was found to be the only anticoagulant drug 
used in haemodialysis unit. The doses of heparin during 
haemodialysis were 5000 IU for the initial bolus and 2500 
IU/hr for continuous infusion. This dose was adjusted in 
some cases like patients with liver diseases and blood 
disorders. Several recent publications have suggested that 
LMWHs may have potential therapeutic advantages over 
normal UFH 8. Laboratory tests like PT and INR were 
evaluated in 28 patients, and these tests were only repeated 
in 8 patients during hospitalization. The risk of 
gastrointestinal bleeding increases by anticoagulant drugs 
especially heparins, so additional occult blood stool test is 
recommended 9. None of the study patients were examined 
for this reason. 
An interesting finding of this study, there was not any drug 
of DOACs prescribed; however, the new anticoagulants have 
obvious advantages over conventional agents. This may be 
due to the high cost of this class and the low patients’ 
income. 
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5. CONCLUSION 
Adherence to anticoagulant therapy plays a major role to 
improve outcomes and reduce the risk of bleeding Medical 
practitioners have multiple anticoagulants administration 
options for the treatment and prophylaxis of VTE. 
Anticoagulants prescription pattern deviation from the 
guidelines depends on characteristics of patients, 
concomitant therapy and physician judgment. Appropriate 
dosing and monitoring of these agents help to evaluate the 
safety and efficacy of anticoagulant drug. Some limitations 
existed in our study; among them were small sample size, 
Single center and Language barrier during patients 
counseling. 
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